SII Receives First Indian License for Hib Vaccine

Serum Institute of India Ltd. (SII Ltd., Pune, India, www.seruminstitute.com) has developed a vaccine against Hib (Haemophilus influenza type b) and obtained a license from the Indian Government for its production. The pilot process technology know-how came from the Netherlands Vaccine Institute (NVI, Bilthoven, the Netherlands, www.nvi-vaccin.nl). This is the first time that through intensive joint development and technology transfer a developing country vaccine manufacturer has developed a Hib vaccine successfully and obtained a license for it.